Clinical Trials Directory

Trials / Completed

CompletedNCT02806024

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study (TAPPAS): A Randomized, Placebo-controlled Double Blind Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
14 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
Female
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this pilot study is to determine if intravenous tranexamic acid (TXA) is effective for reducing blood loss during high risk surgical procedures related to placenta previa and placenta accreta. TXA is currently used in other types of surgery for patients who are expected to have a large blood loss, such as orthopedic or open heart surgery.

Detailed description

To date, no novel or pharmacologic methods of reducing blood loss have been described for women at risk for placenta accreta. Intravenous tranexamic acid (TXA), a drug with anti-fibrinolytic activity, is routinely used in elective orthopedic and cardiac surgery to reduce blood loss. Intravenous tranexamic acid is currently FDA approved for use in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty to reduce peri- and post-operative blood loss and to reduce the need for blood transfusion. There has been growing interest in the application of tranexamic acid in obstetrics and gynecology. In multiple international studies, intravenous TXA has been shown to significantly reduce blood loss when given prophylactically with cesarean delivery or vaginal delivery without an increase in morbidity from adverse thrombotic events. TXA has not been studied in the particular population of patients requiring cesarean hysterectomy for placenta previa or accreta. This inexpensive, low risk medication has potential to greatly reduce perioperative morbidity and cost when used in a high risk obstetrical population.

Conditions

Interventions

TypeNameDescription
DRUGTranexamic Acid
DRUGPlacebo Drug50 cc Normal Saline IV

Timeline

Start date
2016-11-01
Primary completion
2018-07-01
Completion
2018-08-01
First posted
2016-06-20
Last updated
2019-12-03
Results posted
2019-12-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02806024. Inclusion in this directory is not an endorsement.